孟鲁司特钠治疗过敏性哮喘伴变应性鼻炎患儿的疗效及不良反应分析  

Efficacy and adverse reactions of montelukast sodium in the treatment of allergic asthma complicated with allergic rhinitis in children

作　　者：陈钰霜 CHEN Yu-shuang(Department of Pharmacy,Fudan University Affiliated Pediatric Hospital Xiamen Hospital(Xiamen Children's Hospital),Xiamen 361000,China)

机构地区：[1]复旦大学附属儿科医院厦门医院厦门市儿童医院药学部,361000

出　　处：《中国现代药物应用》2022年第24期132-135,共4页Chinese Journal of Modern Drug Application

摘　　要：目的探讨孟鲁司特钠治疗过敏性哮喘伴变应性鼻炎患儿的治疗效果及不良反应。方法回顾性分析72例过敏性哮喘伴变应性鼻炎患儿的临床资料,根据用药方案不同分为观察组和对照组,各36例。两组患儿均予以常规治疗,对照组患儿予以氯雷他定片治疗,观察组患儿予以孟鲁司特钠咀嚼片治疗。对比两组患儿疗效,治疗前后气道反应性指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、最大呼气流量(PEF)],治疗前后哮喘控制及鼻部症状评分,不良反应发生情况。结果观察组治疗总有效率为94.44%,高于对照组的72.22%,差异具有统计学意义(P<0.05)。治疗前,两组患儿的FVC、FEV1、PEF对比差异无统计学意义(P>0.05);治疗后,两组患儿的FVC、FEV1、PEF均高于本组治疗前,观察组FVC、FEV1、PEF分别为(2.68±0.31)L、(2.26±0.52)L、(4.67±0.68)L/s,均高于对照组的(2.32±0.33)L、(1.98±0.46)L、(3.96±0.55)L/s,差异具有统计学意义(P<0.05)。治疗前,两组患儿哮喘控制及鼻部症状评分对比差异均无统计学意义(P>0.05);治疗后,两组患儿的哮喘控制评分均高于本组治疗前、鼻部症状评分均低于本组治疗前,观察组患儿的哮喘控制评分(22.11±1.58)分高于对照组的(16.83±2.34)分,鼻部症状评分(2.85±0.58)分低于对照组的(3.62±0.96)分,差异具有统计学意义(P<0.05)。观察组患儿的不良反应发生率为8.33%,低于对照组的27.78%,差异具有统计学意义(P<0.05)。结论过敏性哮喘伴变应性鼻炎患儿予以孟鲁司特钠治疗,可更好改善哮喘与鼻炎相关症状,使肺部通气提升,疗效确切且安全性较高。Objective To discuss the effect and adverse reactions of montelukast sodium in the treatment of allergic asthma complicated with allergic rhinitis in children.Methods A total of 72 children with allergic asthma and allergic rhinitis were divided into observation group and control group according to different medication regimens,with 36 cases in each group.Children in the control group were treated with loratadine tablets,and children in the observation group were treated with montelukast sodium chewable tablets.Both groups were compared in terms of clinical efficacy,airway responsiveness indexes[forced vital capacity(FVC),forced expiratory volume in one second(FEV1),peak expiratory flow(PEF)],asthma control and nasal symptom score before and after treatment,and the incidence of adverse reactions.Results The total effective rate of the observation group was 94.44%,which was higher than 72.22%of the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in FVC,FEV1 and PEF between the two groups(P>0.05).After treatment,the FVC,FEV1 and PEF of the two groups were higher than those of this group before treatment;the FVC,FEV1 and PEF of the observation group were(2.68±0.31)L,(2.26±0.52)L and(4.67±0.68)L/s,which were higher than(2.32±0.33)L,(1.98±0.46)L and(3.96±0.55)L/s of the control group;the differences were statistically significant(P<0.05).Before treatment,there was no statistically significant difference in asthma control score and nasal symptom score between the two groups(P>0.05).After treatment,the asthma control score of children in both groups was higher than that before treatment in this group,and the nasal symptom score was lower than that before treatment in this group;the asthma control score(22.11±1.58)points in the observation group was higher than(16.83±2.34)points in the control group,and the nasal symptom score(2.85±0.58)points was lower than(3.62±0.96)points in the control group;the differences were statis

关 键 词：孟鲁司特钠 氯雷他定 过敏性哮喘 变应性鼻炎 气道反应性 不良反应 

分 类 号：R765.21[医药卫生—耳鼻咽喉科] R725.6[医药卫生—临床医学]